low density lipoprotein receptor class A domain containing 2Genealiases: []
Q-omics provides the consensus-scored LDLRAD2 profile across patient tissues and cancer cell-line models. LDLRAD2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, LDLRAD2 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, LDLRAD2 RNA expression shows 19,649 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight HNSC, BLCA, and CCRCC as cancer lineages where LDLRAD2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LDLRAD2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LDLRAD2 survival associations across molecular data types. LDLRAD2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LDLRAD2 RNA expression–survival associations across cancer types. High LDLRAD2 expression shows unfavorable associations in MESO, ACC and LGG, but favorable associations in HNSC, KIRC and SKCM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for LDLRAD2 RNA expression.
This table summarizes LDLRAD2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for LDLRAD2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LDLRAD2 shows lower tumor expression in BLCA, UCEC, BRCA and KIRP and higher tumor expression in KIRC and LIHC. The BLCA box plot shows higher LDLRAD2 RNA expression in normal versus tumor tissue (log2 FC = −2.512, t-test p < 0.001).
This table shows molecular features associated with LDLRAD2 in patient tissues and cancer cell lines. In patient samples, LDLRAD2 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set. In cancer cell lines, LDLRAD2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BONE.
